Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLatin American Cooperative Oncology Group
About this trial
This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.
Eligibility criteria
Qualifiers
≥18 years old
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Large-cell neuroendocrine carcinoma (LCNEC) or mixed
Small Cell Lung Cancer (SCLC) or mixed
Disqualifiers
Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer.
Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).
Trial design
Treatments tested in this trial
- Observational study
Treatment groups
200 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Latin American Cooperative Oncology Group
Lead sponsor
Boehringer Ingelheim
Collaborator
Grupo Argentino de Investigación Clínica en Oncología
Collaborator
Grupo de Estudios Clínicos Oncológicos Peruano
Collaborator
Source ClinicalTrials.gov